Ourobionics is officially presenting its co-founding team, formed by professionals with over 50 years of combined expertise in tissue engineering, 3D biofabrication, regenerative medicine, and cyborganics/human-machine interfaces. The company is also formalizing a partnership with Invictech that sets the grounds for developing a multiplex 3D biofabrication platform.
Professor Suwan Jayasinghe (University College London), an expert in tissue engineering and co-inventor of 3D Bioelectrospraying, Cell Electrospinning, and 3D Electrohydrodynamic Jet Bioprinting, has joined Ourobionics as a co-founder and Chief Scientific Officer. Dr. Alireza Dotslashi Pirouz, (DTU Denmark) has joined as a co-founding Chief Technology Officer due to his extensive experience in cyborganics, bioelectronics, and human-machine interface technologies. Additionally, Professor Alvaro Mata has taken up a role as co-founder and Chief Innovation Officer based upon his distinguished achievements within the field of tissue engineering, 3D bioprinting, and self-assembly bioink development.
Finally, Dr. Ahu Arslan Yıldız (Izmir Institute of Technology) has joined as a co-founding advisor to combine her achievements in Magnetic Levitation 3D bioprinting, biomimetics and advanced tissue engineering technology with Ourobionics technology vision. Together with the rest of the team (John Zandbergen- Chief Executive Officer; Elpiniki Tsekou- Chief Financial Officer; Doris Zoric-Marketing Manager; Dr. Stephen G. Gray-Advisor) Ourobionics is the first company to merge 3D biofabrication, tissue engineering, and cyborganic technologies with an ability to create next-generation applications in regenerative medicine and human-machine Interfaces.
After a successful take-off and one strategic alliance formed with Humabiologics in the first quarter, Ourobionics continues to pave the way for the revolution on the market. By entering into an exclusive alliance agreement with Invictech, a USA-based start-up, Ourobionics set the grounds for developing a multiplex 3D biofabrication platform that successfully manipulates electric, magnetic, and electromagnetic fields, in order to create realistic and high throughput 3D tissue models with embedded biosensors and bioelectronics.
Invictech is led by CEO Patrick Yopp with CTO Philip Dettinger (PhD candidate ETH Zurich) and together they have the combined expertise in building next-generation 3D bioprinting machines that will support Ourobionics’ mission to develop and supply up-to-date, cutting-edge technologies in biofabrication and tissue engineering. In addition to its unique approach to maximize the performance of 3D printing, Invictech is also pushing the limits of innovation by utilizing blockchain technology, thus opening doors to advancements in digitalization of the clinical sphere and potential future development of 3D biofabricated cyborganics/biosensors with embedded blockchain technology for better exchange of health data from medical devices over decentralized networks. This collaboration will result in further development of both companies missions and visions along with ideas and design for technologies that empower researchers, developers and producers in various promising fields.
Despite the number of currently available standard extrusion 3D bioprinting technologies, the progress in the field of regenerative medicine seems is being held up due to the inability to create complex tissue models. In addition to poor translational aspects of standard animal-derived biomaterials used in 3D biofabrication, the biggest limitations are imposed by unfeasible means of 3D bioprinting production, resulting in low cell viability, cell deformation from extrusion, slow speed, low functionality, limited metabolic analysis after bioprinting, no micro integration of vessel structures, lack of nanoscale resolution and little relevant clinical potential.
Overcoming these limitations with the advanced tissue engineering technology co-developed by the co-founders of Ourobionics and multiplexed with existing 3D bioprinting at Invictech could assist the industry in achieving its goals and long-term vision. Allowing all researchers, producers, and developers access to these advanced technologies would set the new benchmark in functional and reproducible 3D tissue manufacturing, and regenerative medicine. To go one step further making multiple advanced tissue engineering technologies cost-efficient to clients could potentially disrupt the $10+ Billion tissue engineering market in a similar way to the emergence of affordable desktop 3D bioprinters 6 years ago.